Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes
NCT ID: NCT01465152
Last Updated: 2017-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
182 participants
INTERVENTIONAL
2002-03-06
2004-10-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes
NCT00709917
Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs
NCT00491725
Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes
NCT01720290
Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
NCT00118950
Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs
NCT00819741
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Met
metformin
Adminstered orally during the three main meals for 24 weeks
Rep
repaglinide
Administered orally before the three main meals for 24 weeks
Met+Rep
metformin
Adminstered orally during the three main meals for 24 weeks
repaglinide
Administered orally before the three main meals for 24 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
metformin
Adminstered orally during the three main meals for 24 weeks
repaglinide
Administered orally before the three main meals for 24 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treated by diet for at least 3 months
* Never treated with hypoglycaemic drugs
* HbA1c (glycaemic haemoglobin A1c) on inclusion time superior to 6.5%
Exclusion Criteria
* Advanced vascular complications
* Manifest renal failure
* Manifest hepatic disease
* Pregnancy, breast feeding or intention to become pregnant or if it is considered that the patient is not using adequate contraceptive measures. Adequate contraceptive measures are considered to be an intrauterine device, oral contraceptives and barrier methods
35 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Barcelona, , Spain
Novo Nordisk Investigational Site
Benamargosa, , Spain
Novo Nordisk Investigational Site
Burlata, , Spain
Novo Nordisk Investigational Site
Camas, , Spain
Novo Nordisk Investigational Site
Fuenlabrada, , Spain
Novo Nordisk Investigational Site
Gijón, , Spain
Novo Nordisk Investigational Site
Granada, , Spain
Novo Nordisk Investigational Site
Lugo, , Spain
Novo Nordisk Investigational Site
Madrid, , Spain
Novo Nordisk Investigational Site
Madrid, , Spain
Novo Nordisk Investigational Site
Madrid, , Spain
Novo Nordisk Investigational Site
Portugalete, , Spain
Novo Nordisk Investigational Site
San Adria Del Besos, , Spain
Novo Nordisk Investigational Site
Santander, , Spain
Novo Nordisk Investigational Site
Santander, , Spain
Novo Nordisk Investigational Site
Tegueste, , Spain
Novo Nordisk Investigational Site
Valencia, , Spain
Novo Nordisk Investigational Site
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AGEE-1411
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.